Navigating Treatment-Related Adverse Effects in LAG3 Combination ICI Therapy for Metastatic Melanoma

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Leveraging LAG-3: Innovative Immunotherapy Combinations for First-Line Metastatic Melanoma Treatment

Navigating Treatment-Related Adverse Effects in LAG-3 Combination ICI Therapy for Metastatic Melanoma

ReachMD Healthcare Image
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
0.75 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
  • Overview

    This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.

  • Target Audience

    This activity has been designed to meet the educational needs of Oncologists and Hematology Oncologists, as well as all healthcare providers involved in managing patients with Metastatic Melanoma (MM).

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the synergistic interaction between LAG-3 and other immune checkpoints
    • Evaluate recent practice-changing data on the use of LAG-3/PD-1 combination ICI therapy in patients with metastatic melanoma
    • Select appropriate evidence-based dual ICI treatment regimens for newly diagnosed patients with metastatic melanoma
    • Recognize and manage treatment-related adverse events associated with the use of LAG-3/PD-1 combination ICI regimens
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and Total CME, LLC. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) designates this activity for 0.75 nursing contact hours.  Nurses should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) designates this activity for 0.75 CEUs of pharmacy contact hours.   

    The Universal Activity Number for this program is JA0006235-0000-24-038-H01-P.  This learning activity is knowledge-based.  Your CE credits will be electronically submitted to the NABP upon successful completion of the activity.  Pharmacists with questions can contact NABP customer service at 

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs.

    The following faculty have disclosed:

    ALLISON BETOF WARNER, MD, PHD, faculty for this educational event, is a contracted researcher for Iovance Biotherapeutics, Bristol Myers Squibb, and Trisalis Life Sciences; and receives consulting fees from Bristol Myers Squibb, BluePath Solutions, Immatics, Instil Bio, Iovance Biotherapeutics, Lyell Immunopharma, Novartis, Merck and, Pfizer.

    Hussein Tawbi, MD, PhD, faculty for this educational event, is a contracted researcher for Bristol Myers-Squibb, Novartis, Merck, Genentech, GlaxoSmithKline, EMD Serono, Eisai, Dragonfly Therapeutics and, RAPT Therapeutics; and receives consulting fees from Bristol Myers-Squibb, Genentech, Novartis, Merck, Boxer Capital, Karyopharm,l Iovanc, Eisa, Jazz Pharmaceuticals and, Medicenna.  

  • Planners, Reviewers and Managers Disclosures

    The following reviewers, managers, planners, and relevant staff reported they do not have any financial relationships with any ineligible companies:

    Brian P. McDonough, MD, FAAP has nothing to disclose.

    Megan Reimann, PharmD, BCOP has nothing to disclose.

    Leticia Samaras has nothing to disclose.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Global Learning Collaborative (GLC) and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use their clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner. 

  • Provider(s)/Educational Partner(s)

    It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care. 

  • Commercial Support

    This activity is supported by an independent educational grant from Bristol Myers Squibb.

  • Instructions For Completion

    During the period 04/26/2024 through 04/26/2025, registered participants wishing to receive continuing education credit for this activity must follow these steps:
    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%.
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule17 May 2024